TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. Show more

200 Minuteman Road, Suite 302, Andover, MA, 01810, United States

Medical Devices
Healthcare

Market Cap

2.345B

52 Wk Range

$67.69 - $156.00

Previous Close

$72.90

Open

$72.54

Volume

2,703,718

Day Range

$67.69 - $72.73

Enterprise Value

2.746B

Cash

461.7M

Avg Qtr Burn

N/A

Insider Ownership

3.29%

Institutional Own.

-

Qtr Updated

03/31/26


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Organ Care System (OCS™) Details
Medical Device for Heart Transplant

Approved

Quarterly sales

Organ Care System (OCS™) Details
Medical Device for Liver Transplant

Approved

Quarterly sales

Phase 1

Data readout

Phase 1

Update

Phase 1

Update